Translational Research of Novel Peptide Vaccine

  • Hideki TomiokaEmail author
  • Akiko Tenma
  • Makoto Sakaguchi


Peptide vaccines are in development as potential therapies for many major conditions, including chronic viral infections, allergies, cancer, Alzheimer’s disease, diabetes, hypertension, obesity, and rheumatoid arthritis. The therapeutic vaccines are known to induce neutralizing antibodies against self-molecules and have been clinically tested.

Active immunotherapy has been the most extensively studied approach in Aβ-targeted therapy. To improve the immunogenicity and reduce the adverse event, in the past decade progress of active immunotherapy has been made both in the selection of B cell epitope and the carrier protein. Progress made in peptide-based vaccinations to induce antibody has invigorated the search for vaccine modalities.


Peptide vaccine Active immunotherapy Carrier protein B cell epitope 


  1. Cease KB et al (1987) Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A 84:4249–4253CrossRefGoogle Scholar
  2. Davtyan H et al (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci 33:4923–4934CrossRefGoogle Scholar
  3. Gilman S et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562CrossRefGoogle Scholar
  4. Hernandez I et al (2018) Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care 24:109–112PubMedGoogle Scholar
  5. Nakagami H, Morishita R (2018) Recent advances in therapeutic vaccines to treat hypertension. Hypertension 72:1031–1036CrossRefGoogle Scholar
  6. Nandy A, Basak SC (2016) A brief review of computer-assisted approaches to rational design of peptide vaccines. Int J Mol Sci 17CrossRefGoogle Scholar
  7. Wang CY, Walfield AM (2005) Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 23:2049–2056CrossRefGoogle Scholar
  8. Wiessner C et al (2011) The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31:9323–9331CrossRefGoogle Scholar
  9. Winblad B et al (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597–604CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.FunPep Co., LtdOsakaJapan

Personalised recommendations